Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Getulio Tovar

Psychiatry Lexington, KY Medical Doctor

NPI 1053374082 CMS profile 274720

3175 Custer Dr, Suite #200, Lexington, KY 40517

Open in the dashboard

General payments

$5,266

237 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Getulio Tovar of Lexington, KY is reported in the CMS Open Payments database as having received $5,266 across 237 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $228 2
2024 General $105 1
2023 General $249 3
2022 General $783 46
2021 General $307 13
2020 General $812 46
2019 General $2,783 126

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Getulio Tovar
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Getulio Tovar were reported at $228. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Getulio Tovar Psychiatry median Middle half National median
2019 $2,783 $184 $59–$605 $163
2020 $812 $119 $36–$372 $114
2021 $307 $143 $43–$576 $132
2022 $783 $153 $50–$590 $149
2023 $249 $170 $56–$651 $160
2024 $105 $179 $57–$673 $164
2025 $228 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $664 21 payments
  2. Teva Pharmaceuticals USA, Inc. $537 13 payments
  3. AbbVie, Inc. $479 26 payments
  4. Neurocrine Biosciences, Inc. $469 11 payments
  5. Allergan Inc. $449 43 payments
  6. Janssen Pharmaceuticals, Inc $448 14 payments
  7. Sunovion Pharmaceuticals Inc. $408 24 payments
  8. Lundbeck LLC $303 21 payments
  9. Axsome Therapeutics, Inc. $250 4 payments
  10. Ironshore Pharmaceuticals Inc. $209 6 payments
  11. Other $1,052 54 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,185 236 payments
  2. Education $81 1 payment
Products named General payments · program years 2019–2025
  1. REXULTI $603 17 payments
  2. VRAYLAR Neuroscience $479 26 payments
  3. INGREZZA $455 10 payments
  4. VRAYLAR Neuroscience $449 43 payments
  5. AUSTEDO $438 11 payments
  6. SPRAVATO $417 11 payments
  7. LATUDA $408 24 payments
  8. Auvelity $250 4 payments
  9. HETLIOZ $177 9 payments
  10. Jornay PM 20mg capsules (Bottle of 100) $174 4 payments
  11. Other $1,902 98 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 66 drugs

Part D claims

6,312

Median for Psychiatry: 574

Drug cost

$435,531

Median for Psychiatry: $27,624

Branded share of claims

17.2%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 37 $181,515
Rexulti Brexpiprazole Brand 56 $79,519
Vraylar Cariprazine Hcl Brand 30 $42,417
Trintellix Vortioxetine Hydrobromide Brand 31 $20,091
Aripiprazole Generic 260 $9,658
Vyvanse Lisdexamfetamine Dimesylate Brand 16 $5,982
Paliperidone Er Paliperidone Brand 30 $5,640
Buspirone Hcl Generic 400 $5,188
Venlafaxine Hcl Er Venlafaxine Hcl Brand 225 $5,113
Duloxetine Hcl Generic 322 $4,734

The 10 drugs with the highest cost, of 66 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$31,911

Medicare's payments for the services billed

Medicare patients

118

Average age 69

Services billed

369

74 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Depression 70%
Arthritis 57%
Diabetes 30%
Ischemic heart disease 28%
COPD 26%
Atrial fibrillation 20%
Chronic kidney disease 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
  • Axsome Therapeutics, Inc. $105
$105 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

237 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record